<DOC>
	<DOCNO>NCT00744887</DOCNO>
	<brief_summary>The objective determine effect different ritonavir dos darunavir ( DRV ) oral exposure follow once-daily oral dose DRV/rtv 7 day , order establish optimal ritonavir boost dose DRV evaluate short-term safety tolerability .</brief_summary>
	<brief_title>TMC114-TiDP3-C181 : Study Assess Pharmacokinetics Darunavir ( DRV ) With Different Doses Ritonavir Healthy Volunteers .</brief_title>
	<detailed_description>This Phase I , open-label , randomize ( study drug assign chance ) , 3-way crossover trial healthy volunteer assess pharmacokinetics darunavir ( DRV ) , co-administered different dos ritonavir . The trial population consist 18 healthy adult volunteer . During 3 subsequent session , volunteer receive randomize way : Treatments A , B C. In Treatment A , 800 mg DRV once-daily 100 mg ritonavir once-daily administer . In Treatment B , 800 mg DRV once-daily 50 mg ritonavir once-daily administer . In Treatment C , 800 mg DRV once-daily 20 mg ritonavir once-daily administer . All treatment administer 7 day intake DRV ritonavir feed condition . DRV formulate 400 mg tablet ; ritonavir formulate oral solution contain 80mg/mL ritonavir . In treatment session , full pharmacokinetic profile DRV ritonavir determine 24 hour administration Day 1 72 hour administration Day 7 . There washout period least 7 day subsequent treatment . Safety tolerability evaluate continuously throughout trial . During 3 subsequent session , volunteer receive randomize way Treatments A , B C. In Treatment A , 800/100 mg DRV/rtv once-daily administer . In Treatment B , 800/50 mg DRV/rtv once-daily administer . In Treatment C , 800/20 mg DRV/rtv once-daily administer . All treatment administer 7 day . DRV formulate 400 mg tablet ; ritonavir formulate oral solution contain 80mg/mL ritonavir .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination , medical history , electrocardiogram ( ECG ) , vital sign , result blood biochemistry , blood coagulation hematology test urinalysis carry screen A positive HIV1 HIV2 test screen Hepatitis A , B , C infection ( confirm hepatitis A antibody IgM , hepatitis B surface antigen [ positive hep B PCR ] , hepatitis C virus antibody , respectively ) Screening Any history significant skin disease , limited , rash eruption , food drug allergy , dermatitis , eczema , psoriasis , folliculitis , urticaria Use concomitant medication , include overthecounter product , herbal preparation dietary supplement . Concomitant medication must discontinue least 14 day first dose trial medication except paracetamol ( acetaminophen ) , hormone replacement therapy hormonal contraceptive Participation investigational drug trial within 60 day prior first intake trial medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>TMC114-TiDP3-C181</keyword>
	<keyword>TMC114-C181 , health volunteer , Darunavir , ritonavir oral solution</keyword>
</DOC>